Search research articles
Contact Us
Filters
Showing results (371-380 of 381) with videos related to
Page
of 39
Sort By:
Brain : a Journal of Neurology
|
February 4, 2025
The landscape of autosomal-dominant Alzheimer's disease: global distribution and age of onset
Haiyan Liu, Thomas W Marsh, Xinyu Shi, et al.
Acta Neuropathologica
|
June 3, 2025
Immunohistochemical evaluation of a trial of gantenerumab or solanezumab in dominantly inherited Alzheimer disease
Charles D Chen, Erin E Franklin, Yan Li, et al.
JAMA Neurology
|
April 29, 2024
Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical Trial
Olivia Wagemann, Haiyan Liu, Guoqiao Wang, et al.
Annals of Neurology
|
September 24, 2022
Amyloid-Related Imaging Abnormalities in the DIAN-TU-001 Trial of Gantenerumab and Solanezumab: Lessons from a Trial in Dominantly Inherited Alzheimer Disease
Nelly Joseph-Mathurin, Jorge J Llibre-Guerra, Yan Li, et al.
Neurology
|
January 26, 2021
Longitudinal Accumulation of Cerebral Microhemorrhages in Dominantly Inherited Alzheimer Disease
Nelly Joseph-Mathurin, Guoqiao Wang, Kejal Kantarci, et al.
Medrxiv : the Preprint Server for Health Sciences
|
February 6, 2026
Anti-CD320 Autoantibodies and Central Nervous System Vitamin B12 Deficiency in Idiopathic Myelopathy
John V Pluvinage, David Acero-Garces, Giacomo Greco, et al.
Nature Neuroscience
|
July 10, 2023
Positron emission tomography and magnetic resonance imaging methods and datasets within the Dominantly Inherited Alzheimer Network (DIAN)
Nicole S McKay, Brian A Gordon, Russ C Hornbeck, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
February 21, 2024
Presenilin-1 mutation position influences amyloidosis, small vessel disease, and dementia with disease stage
Nelly Joseph-Mathurin, Rebecca L Feldman, Ruijin Lu, et al.
The Lancet. Neurology
|
March 22, 2025
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trial
Randall J Bateman, Yan Li, Eric M McDade, et al.
Nature Medicine
|
June 22, 2021
A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease
Stephen Salloway, Martin Farlow, Eric McDade, et al.
Page
of 39
Search research articles
Search
Showing results (371-380 of 381) with videos related to
Sort By:
Page
of 39
Brain : a Journal of Neurology
|
February 4, 2025
The landscape of autosomal-dominant Alzheimer's disease: global distribution and age of onset
Haiyan Liu, Thomas W Marsh, Xinyu Shi, et al.
Acta Neuropathologica
|
June 3, 2025
Immunohistochemical evaluation of a trial of gantenerumab or solanezumab in dominantly inherited Alzheimer disease
Charles D Chen, Erin E Franklin, Yan Li, et al.
JAMA Neurology
|
April 29, 2024
Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical Trial
Olivia Wagemann, Haiyan Liu, Guoqiao Wang, et al.
Annals of Neurology
|
September 24, 2022
Amyloid-Related Imaging Abnormalities in the DIAN-TU-001 Trial of Gantenerumab and Solanezumab: Lessons from a Trial in Dominantly Inherited Alzheimer Disease
Nelly Joseph-Mathurin, Jorge J Llibre-Guerra, Yan Li, et al.
Neurology
|
January 26, 2021
Longitudinal Accumulation of Cerebral Microhemorrhages in Dominantly Inherited Alzheimer Disease
Nelly Joseph-Mathurin, Guoqiao Wang, Kejal Kantarci, et al.
Medrxiv : the Preprint Server for Health Sciences
|
February 6, 2026
Anti-CD320 Autoantibodies and Central Nervous System Vitamin B12 Deficiency in Idiopathic Myelopathy
John V Pluvinage, David Acero-Garces, Giacomo Greco, et al.
Nature Neuroscience
|
July 10, 2023
Positron emission tomography and magnetic resonance imaging methods and datasets within the Dominantly Inherited Alzheimer Network (DIAN)
Nicole S McKay, Brian A Gordon, Russ C Hornbeck, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
February 21, 2024
Presenilin-1 mutation position influences amyloidosis, small vessel disease, and dementia with disease stage
Nelly Joseph-Mathurin, Rebecca L Feldman, Ruijin Lu, et al.
The Lancet. Neurology
|
March 22, 2025
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trial
Randall J Bateman, Yan Li, Eric M McDade, et al.
Nature Medicine
|
June 22, 2021
A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease
Stephen Salloway, Martin Farlow, Eric McDade, et al.
Page
of 39